Meetings - The ASCO Post

/ High-Risk HR-Positive, HER2-Negative Early-Stage Breast Cancer

Case 3: Toxicity Management in ER-Positive Breast Cancer

This is Part 3 of High-Risk HR-Positive, HER2-Negative Early-Stage Breast Cancer: Bridging Evidence, Risk Identification, and Real-World Practice, a three-part video roundtable series. Scroll down to ...

breast cancer

/ High-Risk HR-Positive, HER2-Negative Early-Stage Breast Cancer

Case 2: High-Risk ER-Positive Early Breast Cancer With gBRCAm

This is Part 2 of High-Risk HR-Positive, HER2-Negative Early-Stage Breast Cancer: Bridging Evidence, Risk Identification, and Real-World Practice, a three-part video roundtable series. Scroll down to ...

breast cancer

/ High-Risk HR-Positive, HER2-Negative Early-Stage Breast Cancer

Case 1: Understanding Risk of Recurrence in ER-Positive Early Breast Cancer

This is Part 1 of High-Risk HR-Positive, HER2-Negative Early-Stage Breast Cancer: Bridging Evidence, Risk Identification, and Real-World Practice, a three-part video roundtable series. Scroll down to ...

High-Risk HR-Positive, HER2-Negative Early-Stage Breast Cancer

Case 3: Toxicity Management in ER-Positive Breast Cancer

Case 2: High-Risk ER-Positive Early Breast Cancer With gBRCAm

Case 1: Understanding Risk of Recurrence in ER-Positive Early Breast Cancer

Pooled Analysis of 5-Year Outcomes With Ultra-Hypofractionated SABR in Primary Renal Cell Carcinoma

FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer

ASCO Remembers Karnofsky Award Recipient Maura Gillison Pioneer in HPV-Associated Cancers

Novel Risk Score Stratifies Major Bleeding Risks in Patients With VTE on DOACs

Long-Term Outcomes With SABR in Primary Kidney Cancer